Adults with castration-resistant prostate cancer invited to be in a research study

IRB/UVA Tracking #
Principal Investigator
Michael Devitt
Jennifer Drake
Contact Email
Contact Phone
Official Trial Title
A Phase 1, Open-Label, Dose Finding, First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 when Administered with Enzalutamide, Abiraterone, or Apalutamide in Subjects with Non-Metastatic or Metastatic Castration-Resistant
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have prostate cancer. The purpose of this study is to look at the safety and the maximum tolerated dose through single and multiple dosing of the study drug when given orally to adult male subjects with castration-resistant prostate cancer (CRPC) who have completed at least 4 weeks of prior continuous therapy with fixed stable dose enzalutamide, abiraterone or apalutamide prior to starting study treatment, with no change in dose for at least 2 weeks prior to screening.

If you qualify and decide to take part in this study, your part in the study is expected to last up to 8 months, the time from the Screening Visit to the End of Study Visit, including 1 month for screening, 6 months for study treament and 1 month for safety follow-up. The study will be made up of two parts. In both Part 1 and Part 2 of the study, there will be 6 study treatment cycles which will be 28 days each.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.

Additional information can be found here:


Compensation: $50 per completed visit, Reimbursement: Up to $175 per night for a hotel room